



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



PRODUCT INFORMATION

GAT229

Item No. 24486

CAS Registry No.: 889860-85-9

Formal Name: 3-[(1S)-2-nitro-1-phenylethyl]-2-phenyl-1H-indole

MF: C₂₂H₁₈N₂O₂


FW: 342.4

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GAT229 is supplied as a solid. A stock solution may be made by dissolving the GAT229 in the solvent of choice, which should be purged with an inert gas. GAT229 is soluble in the organic solvent DMSO at a concentration of approximately 20 mg/ml.

Description

GAT229 is a positive allosteric modulator of cannabinoid receptor 1 (CB₁) and the S-(-) enantiomer of the CB₁ modulator GAT211.^{1,2} It does not activate the receptor on its own but enhances the binding and activity of CB agonists. GAT229 (1 μM) enhances the binding of the CB₁ full agonist CP 55,940 to CHO cells expressing human recombinant CB₁ (hCB₁), as well as the activity of 2-arachidonoyl glycerol (2-AG; Item No. 62160), arachidonoyl ethanolamide (AEA; Item No. 90050), and CP 55,940 in arrestin2 recruitment assays and increases ERK1/2 and PLCβ3 phosphorylation in HEK293 cells expressing hCB₁. GAT229 (1 μM) enhances depolarization-induced suppression of excitation but does not inhibit excitatory postsynaptic currents (EPSCs) in murine autaptic hippocampal neurons.² GAT229 (0.2%, topical) reduces intraocular pressure by 5.8 and 7.7 mm Hg after 6 and 12 hours, respectively, in a transgenic mouse model of ocular hypertension using nose, ear, eye mutation (nee) mice.³

References

1. Laprairie, R.B., Kulkarni, P.M., Deschamps, J.R., et al. Enantiospecific allosteric modulation of cannabinoid 1 receptor. *ACS Chem Biol.* **8**(6), 1188-1203 (2017).
2. Mitjavila, J., Yin, D., Kulkarni, P.M., et al. Enantiomer-specific positive allosteric modulation of CB₁ signaling in autaptic hippocampal neurons. *Pharmacol. Res.* **129**, 475-481 (2018).
3. Cairns, E.A., Szczesniak, A.-M., Straiker, A.J., et al. The *in vivo* effects of the CB₁-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice. *J. Ocul. Pharmacol. Ther.* **33**(8), 582-590 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.